This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
DSIP (5 mg Vial)
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (9 amino acids) first isolated from rabbit brain tissue and studied for its effects on sleep architecture and stress modulation[1][2]. Research indicates DSIP may promote delta-wave (slow-wave) sleep, modulate cortisol and ACTH levels, and exhibit stress-protective properties[3][4].
Quick Reference
What is DSIP?
Research overview based on the cited scientific literature.
• Goal: Support healthy sleep architecture and stress modulation over time[3][4].
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Storage Instructions
Storage and stability depend on the exact material and formulation. General protein-stability and lyophilization reviews describe formulation and degradation considerations[8][9]. Use verified material-specific documentation for storage conditions and usable lifetime, and record preparation and storage conditions. This page does not provide a validated DSIP-specific shelf life.
How is DSIP studied?
DSIP (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) was first characterized in 1977 as a sleep-modulating factor isolated from rabbit brain[1]. Mechanistic studies suggest DSIP may influence sleep by modulating GABAergic transmission and interacting with opioid receptor systems[10]. Research indicates it can increase delta-wave (slow-wave) sleep duration without significantly altering REM sleep architecture[3]. Beyond sleep, DSIP has demonstrated stress-protective and adaptogenic properties in various models, potentially through modulation of the hypothalamic-pituitary-adrenal axis[4][11].
What does the research report about DSIP?
Observations from preclinical and clinical literature.
• May promote deeper, more restorative slow-wave sleep and improve subjective sleep quality[3][5].
• Research suggests potential stress-protective and anxiolytic-like effects[4][11].
• Some studies indicate DSIP does not induce pharmacological tolerance with continued use[2].
• Generally well tolerated in human studies; occasional mild injection-site reactions may occur with subcutaneous administration.
• This research overview does not recommend personal treatment cycles or scheduled breaks.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
What are the limitations of the research on DSIP?
Evidence should be interpreted within the population, experimental model, formulation, route, outcome measures, and study design used in each cited source. Preclinical or early-stage findings do not establish clinical efficacy, safety, or approved human use. Where human evidence is available, results should not be generalized beyond the populations and conditions actually studied.
